Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony M Hunter

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Hematology (Amsterdam, Netherlands)|October 7, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phaseEhab Atallah, Michael S Broder, Onyee Chan, et al.
Blood Cancer Discovery|September 2, 2022
Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse OutcomesMeghan C Ferrall-Fairbanks, Abhishek Dhawan, Brian Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic LeukemiaAnthony M Hunter, Hannah Newman, Amy E Dezern, et al.
JAMA Oncology|November 21, 2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical TrialElias Jabbour, Vivian G Oehler, Paul B Koller, et al.
Blood|October 26, 2021
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformationXiaona You, Fabao Liu, Moritz Binder, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic LeukemiaLuca Lanino, Anthony M Hunter, Nico Gagelmann, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Hematology (Amsterdam, Netherlands)|October 7, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phaseEhab Atallah, Michael S Broder, Onyee Chan, et al.
Blood Cancer Discovery|September 2, 2022
Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse OutcomesMeghan C Ferrall-Fairbanks, Abhishek Dhawan, Brian Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2021
Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic LeukemiaAnthony M Hunter, Hannah Newman, Amy E Dezern, et al.
JAMA Oncology|November 21, 2024
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical TrialElias Jabbour, Vivian G Oehler, Paul B Koller, et al.
Blood|October 26, 2021
Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformationXiaona You, Fabao Liu, Moritz Binder, et al.
Lancet Regional Health. Americas|June 17, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET)Brandi N Reeves, Firas El Chaer, Lynda Foltz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 27, 2026
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic LeukemiaLuca Lanino, Anthony M Hunter, Nico Gagelmann, et al.
Pageof 2